Voyager Therapeutics (VYGR)

Voyager Therapeutics (VYGR) Financial Statements


Voyager Therapeutics Financial Overview

Voyager Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.048; its P/E ratio is -168.19; Voyager Therapeutics is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is $-0.41. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 19.52M$ 90.06M$ 4.61M$ 4.85M$ 150.48M
Gross Profit$ 19.50M$ 90.06M$ 4.61M$ 4.85M$ 150.48M
EBIT$ -16.18M$ 54.06M$ -26.08M$ -22.15M$ 122.88M
EBITDA$ -14.99M$ 55.40M$ -26.94M$ -21.07M$ 123.94M
Net Income Common Stockholders$ -11.33M$ 56.40M$ -25.90M$ -22.21M$ 124.04M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 399.57M$ 230.88M$ 252.94M$ 272.75M$ 273.31M
Total Assets$ 469.61M$ 351.28M$ 294.65M$ 315.54M$ 336.29M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -399.57M$ -230.88M$ -252.94M$ -272.75M$ -273.31M
Total Liabilities$ 128.71M$ 114.96M$ 118.43M$ 116.51M$ 119.33M
Stockholders Equity$ 340.90M$ 236.32M$ 176.22M$ 199.00M$ 216.96M
Cash Flow-
Free Cash Flow$ 56.63M$ -24.52M$ -21.83M$ -2.04M$ 123.06M
Operating Cash Flow$ 58.77M$ -23.76M$ -21.05M$ -835.00K$ 123.56M
Investing Cash Flow$ -96.06M$ 26.83M$ -158.30M$ -24.66M$ 14.49M
Financing Cash Flow$ 112.86M$ 460.00K$ 331.00K$ 1.55M$ 31.31M
Currency in USD

Voyager Therapeutics Earnings and Revenue History

Voyager Therapeutics Debt to Assets

Voyager Therapeutics Cash Flow

Voyager Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis